PureTech’s Failure Leaves Long COVID Treatment Hopes Looking Thin
But Candidate Promising In IPF
Executive Summary
PureTech’s LYT-100 has failed to show benefit over placebo in long COVID, and raised doubts about how treatable the condition is – in contrast to the drug’s other potential use in idiopathic pulmonary fibrosis.